Addex Therapeutics (FRA:APE) Other Financing: €-0.02 Mil (TTM As of Mar. 2026)


What is Addex Therapeutics Other Financing?

Addex Therapeutics FRA:APE -4.60% Other Financing is €-0.02 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Addex Therapeutics's Other Financing for the three months ended in Mar. 2026 was €-0.01 Mil.

Addex Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02 Mil.

Addex Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Other Financing Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.65 1.74 3.44 -0.04 -0.01

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.01 -0.01

Addex Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.02 Mil mean?
Addex Therapeutics (FRA:APE) has a Other Financing of €-0.02 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Addex Therapeutics and its competitors.
Is Addex Therapeutics' Other Financing too high?
Addex Therapeutics' current Other Financing is €-0.02 Mil.
How does Addex Therapeutics' Other Financing compare to VRTX and REGN?
Addex Therapeutics' Other Financing of €-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Addex Therapeutics and its competitors. Addex Therapeutics's current Other Financing is €-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (FRA:APE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 315% above its estimated fair value. The current Other Financing is €-0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current Other Financing is €-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.